Abstract 179P
Background
Whether postoperative adjuvant transarterial chemoembolization (PA-TACE) can prolong overall survival (OS) in patients with resected hepatocellular carcinoma (HCC) remains confusion. We aimed to assess and compare the efficacy of PA-TACE and surgery alone in patients with resected HCC.
Methods
Data from patients who underwent surgery were selected and collected for retrospectively analysis. A propensity-score 1:1 matching analysis was performed. The overall survival was analyzed by the Kaplan-Meier method, and survival outcomes for patients who underwent PA-TACE were compared with those who underwent surgery alone.
Results
A total 286 patients (PA-TACE vs surgery alone, 143:143) were identified and selected after a propensity-score 1:1 matching analysis. No significant difference was observed in each variable in the matched data. And, all Kaplan-Meier curves for overall survival between PA-TACE and surgery alone group showed significance before and after propensity score matching (P = 0.0065 and P < 0.001, respectively). Subgroup analysis showed patients with low BCLC stage and low albumin-bilirubin grade had a better overall survival in the PA-TACE group.
Conclusions
Compared to surgery alone, PA-TACE could prolonger overall survival in patients with resected HCC, especially for who with low BCLC stage and/or low albumin-bilirubin grade.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Xiujun Cai.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
221P - Comparative analysis of first-line immune checkpoint inhibitor versus carboplatin-based chemotherapy for cisplatin-ineligible metastatic urothelial carcinoma: A multicenter, retrospective real-world evidence
Presenter: Hsiang‐Lan Lai
Session: Poster display session
Resources:
Abstract
222P - Does tumor grade really improve the prognostic ability of the staging system for men with penile cancer: A SEER database analysis
Presenter: Ravi Kanodia
Session: Poster display session
Resources:
Abstract
223TiP - EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma
Presenter: Daniel Petrylak
Session: Poster display session
Resources:
Abstract
230P - Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort
Presenter: Lingying Wu
Session: Poster display session
Resources:
Abstract
231P - Cost-effectiveness of olaparib vs routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
Presenter: David SP Tan
Session: Poster display session
Resources:
Abstract
233P - Incorporation of correlative studies in ovarian cancers in the era of precision medicine: Assessment of accountability and utility
Presenter: Nadia Hitchen
Session: Poster display session
Resources:
Abstract
234P - Implementation of mainstream BRCA testing in epithelial ovarian cancer in a tertiary centre
Presenter: Edbert Wong
Session: Poster display session
Resources:
Abstract
235P - The efficacy of radiation therapy in ovarian carcinoma: A propensity score analysis of a population-based study
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
236P - Front-line maintenance therapy for platinum-sensitive ovarian cancer: What’s next PARP inhibitors?
Presenter: Han Gong
Session: Poster display session
Resources:
Abstract
237P - PARP inhibitor in platinum resistant ovarian cancer: Single center real world experience
Presenter: Saphalta Baghmar
Session: Poster display session
Resources:
Abstract